- Home
- CGEM
as of 01-28-2026 3:38pm EST
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 671.7M | IPO Year: | 2021 |
| Target Price: | $28.13 | AVG Volume (30 days): | 707.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.68 - $13.33 | Next Earning Date: | 02-26-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered CGEM Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cullinan Oncology Inc. (CGEM)
Chief Scientific Officer
Avg Cost/Share
$12.30
Shares
4,000
Total Value
$49,200.00
Owned After
128,635
SEC Form 4
President and CEO
Avg Cost/Share
$10.01
Shares
9,922
Total Value
$99,319.22
Owned After
420,699
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$10.01
Shares
1,345
Total Value
$13,463.45
Owned After
128,635
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$11.90
Shares
995
Total Value
$11,840.50
Owned After
128,635
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$12.38
Shares
2,148
Total Value
$26,592.24
Owned After
128,635
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$12.30
Shares
4,000
Total Value
$49,200.00
Owned After
128,635
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Jan 22, 2026 | Sell | $12.30 | 4,000 | $49,200.00 | 128,635 | |
| AHMED NADIM | CGEM | President and CEO | Dec 23, 2025 | Sell | $10.01 | 9,922 | $99,319.22 | 420,699 | |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Dec 19, 2025 | Sell | $10.01 | 1,345 | $13,463.45 | 128,635 | |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Dec 15, 2025 | Sell | $11.90 | 995 | $11,840.50 | 128,635 | |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Dec 12, 2025 | Sell | $12.38 | 2,148 | $26,592.24 | 128,635 | |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Nov 24, 2025 | Sell | $12.30 | 4,000 | $49,200.00 | 128,635 |
Compare CGEM vs Leading Stocks
See how CGEM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CGEM Cullinan Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.